This trial is conducted in Europe. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 70 in healthy male subjects.

Inclusion Criteria:

• Considered generally healthy upon completion of medical history and physical examination, as judged by the investigator
• Body Mass Index (BMI) between 19.0-30.0 kg/m^2
• Glycohemoglobin (HbA1c) within laboratory normal range
• Non-smokers

Exclusion Criteria:

• Clinically significant abnormal haematology, biochemistry, urinalysis or ECG (electrocardiogram) screening tests, as judged by the investigator
• Liver enzyme values (ALAT and ASAT) exceeding 2 times the upper reference limit according to the local laboratory
• A history of any illness that, in the opinion of the Investigator and/or Sponsor, might confound the results of the trial or pose additional risk in administering the investigational product to the subject
• History of or current addiction to alcohol or drugs of abuse as determined by the investigator (positive urine drug screen and breath alcohol screen)
• HIV (human immunodeficiency virus), Hepatitis B or C positive
• Subjects with a first-degree relative with diabetes mellitus
• A history of multiple and/or severe allergies to drugs or foods or a history of anaphylactic reactions
• Known or suspected allergy to trial product or related products
• Smoking during the past three months